OncoMatch/Clinical Trials/NCT05526989
Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma
Is NCT05526989 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Dostarlimab and Niraparib for penile carcinoma.
Treatment: Dostarlimab · Niraparib — The purpose of the study is to evaluate the efficacy and safety of the combination of niraparib and dostarlimab in patients participants with advanced relapsed/refractory penile cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Penile Carcinoma
Disease stage
Required: Stage III, IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: platinum-based chemotherapy — locally advanced or neoadjuvant/adjuvant or in combination with radiation therapy
Participants who have progressed or had tolerance problems to no more than one prior line of therapy in the locally advanced setting or post platinum-based chemotherapy, including in a neoadjuvant or adjuvant setting or in combination with radiation therapy.
Cannot have received: immune-oncology therapy (anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti-CTLA-4, indoleamine 2,3-dioxygenase pathway inhibitors, cancer vaccines, adoptive cell therapies, cytokine therapies)
Participants must not have received any prior immune-oncology regimens, including but not limited to checkpoint inhibitors such as anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T cell co-stimulation or checkpoint pathways, indoleamine 2,3-dioxygenase pathway inhibitors, cancer vaccines, adoptive cell therapies, or other cytokine therapies
Lab requirements
Blood counts
Demonstrated adequate organ function, as defined in protocol, within 28 days of treatment initiation
Kidney function
Demonstrated adequate organ function, as defined in protocol, within 28 days of treatment initiation
Liver function
Demonstrated adequate organ function, as defined in protocol, within 28 days of treatment initiation
Demonstrated adequate organ function, as defined in protocol, within 28 days of treatment initiation
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Moffitt Cancer Center · Tampa, Florida
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify